Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration
Maintenance therapy with bevacizumab may be more beneficial for patients with platinum-sensitive recurrent ovarian cancer who have a history of PARPi administration.
Authors
- Mai Momomura (ORCID: https://orcid.org/0000-0002-4749-8403)
- Tohru Morisada (ORCID: https://orcid.org/0000-0002-4223-1291)
- H. Matsumoto (ORCID: https://orcid.org/0000-0002-7646-6638)
- Yoichi Kobayashi (ORCID: https://orcid.org/0000-0002-8474-0625)
- Hiromi Shibuya (ORCID: https://orcid.org/0000-0003-3305-8308)
- Fumio Asano (ORCID: https://orcid.org/0000-0001-6734-9870)
Institutions
- Kyorin University (JP)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3802/jgo.2026.37.e15
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00